HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates

Constitutively stabilized HSP90 client proteins are crucial for cancer cell survival and proliferation. Thus, despite—or perhaps because of—their pleiotropic effects on variety of critical oncoproteins, HSP90 inhibitors represent a promising new class of anticancer drugs. We identified MIF as an ess...

Descripción completa

Detalles Bibliográficos
Autores principales: Schulz, Ramona, Dobbelstein, Matthias, Moll, Ute M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518525/
https://www.ncbi.nlm.nih.gov/pubmed/23243616
http://dx.doi.org/10.4161/onci.21173
_version_ 1782252569230311424
author Schulz, Ramona
Dobbelstein, Matthias
Moll, Ute M.
author_facet Schulz, Ramona
Dobbelstein, Matthias
Moll, Ute M.
author_sort Schulz, Ramona
collection PubMed
description Constitutively stabilized HSP90 client proteins are crucial for cancer cell survival and proliferation. Thus, despite—or perhaps because of—their pleiotropic effects on variety of critical oncoproteins, HSP90 inhibitors represent a promising new class of anticancer drugs. We identified MIF as an essential HSP90 client protein in a murine model of Her2-overexpressing breast cancer.
format Online
Article
Text
id pubmed-3518525
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-35185252012-12-14 HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates Schulz, Ramona Dobbelstein, Matthias Moll, Ute M. Oncoimmunology Author's View Constitutively stabilized HSP90 client proteins are crucial for cancer cell survival and proliferation. Thus, despite—or perhaps because of—their pleiotropic effects on variety of critical oncoproteins, HSP90 inhibitors represent a promising new class of anticancer drugs. We identified MIF as an essential HSP90 client protein in a murine model of Her2-overexpressing breast cancer. Landes Bioscience 2012-11-01 /pmc/articles/PMC3518525/ /pubmed/23243616 http://dx.doi.org/10.4161/onci.21173 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Schulz, Ramona
Dobbelstein, Matthias
Moll, Ute M.
HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates
title HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates
title_full HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates
title_fullStr HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates
title_full_unstemmed HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates
title_short HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates
title_sort hsp90 inhibitor antagonizing mif: the specifics of pleiotropic cancer drug candidates
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518525/
https://www.ncbi.nlm.nih.gov/pubmed/23243616
http://dx.doi.org/10.4161/onci.21173
work_keys_str_mv AT schulzramona hsp90inhibitorantagonizingmifthespecificsofpleiotropiccancerdrugcandidates
AT dobbelsteinmatthias hsp90inhibitorantagonizingmifthespecificsofpleiotropiccancerdrugcandidates
AT mollutem hsp90inhibitorantagonizingmifthespecificsofpleiotropiccancerdrugcandidates

Ejemplares similares